Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562

Cancer Letters

Volumn 289, Issue 1, 2010, Pages 46-52

  Chan, Kin Tak ^a   Li, Kwan ^a   Liu, Shiu Lam ^a   Chu, Kee Hung ^a   Toh, Melvin ^a   Xie, Wei Dong ^a  

^a (Holdings) Inc   (Hong Kong)

Author keywords

Cucurbitacin B; K562; Leukemia; Raf MEK ERK pathway; STAT3

Indexed keywords

CUCURBITACIN; CUCURBITACIN B; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RAF PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRAIN K 562; CONCENTRATION RESPONSE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MOLECULAR INTERACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLOW CYTOMETRY; HUMANS; K562 CELLS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; RAF KINASES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRITERPENES;

CUCURBITACEAE;

EID: 75949101396     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.07.015     Document Type: Article

References (39)

1. Chambliss O.L., and Jone C.M. Cucurbitacins: specific insect attractants in Cucurbitaceae. Science 153 3742 (1996) 1392-1393
2. Chen J.C., Chiu M.H., Nie R.L., Cordell G.A., and Qiu S.X. Cucurbitacins and cucurbitane glycosides: structures and biological activities. Nat. Prod. Rep. 22 3 (2005) 386-399
3. Jayaprakasam B., Seeram N.P., and Nair M.G. Anticancer and anti-inflammatory activities of cucurbitacins from Cucurbita andreana. Cancer Lett. 189 1 (2003) 11-16
4. Agil A., Miro M., Jimenez J., Aneiros J., Caracuel M.D., Garcia-Granados A., and Navarro M.C. Isolation of anti-hepatotoxic principle from the juice of Ecballium elaterium. Planta Med. 65 7 (1999) 673-675
5. Blaskovich M.A., Sun J., Cantor A., Turkson J., Jove R., and Sebti S.M. Discovery of JSI-124 (cucurbitacin I), a selective Janus Kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 63 3 (2003) 1270-1279
6. Duncan K.L., Duncan M.D., Alley M.C., and Sausville E.A. Cucurbitacin E-induced disruption of the actin and vimentin cytoskeleton in prostate carcinoma cells. Biochem. Pharmacol. 52 10 (1996) 1553-1560
7. Meng D., Qiang S., Lou L., and Zhao W. Cytotoxic cucurbitane-type triterpenoids from Elaeocarpus hainanensis. Planta Med. 74 14 (2008) 1741-1744
8. Farias M.R., Schenkel E.P., Mayer R., and Rucker G. Cucurbitacins as constituents of Wibrandia ebracteata. Planta Med. 59 3 (1993) 272-275
9. Peter R.R., Farias M.R., and Ribeiro-do-Valle R.M. Anti-inflammatory and analgesic effects of cucurbitacins from Wibrandia ebracteata. Planta Med. 63 6 (1997) 525-528
10. Yesilada E., Tanaka S., Sezik E., and Tabata M. Isolation of an anti-inflammatory principle from the fruit juice of Ecballium elaterium. J. Nat. Prod. 51 3 (1988) 504-508
11. Zhang M., Zhang H., Sun C., Shan X., Yang X., Li-Ling J., and Deng Y. Target constitutive activation of signal transducer and activator of transcription 3 in human hepatocellular carcinoma cells by cucurbitacin B. Cancer Chemother. Pharmacol. (2008)
12. Wakimoto N., Yin D., O'Kelly J., Haritunians T., Karlan B., Said J., Xing H., and Koeffler H.P. Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo. Cancer Sci. 99 9 (2008) 1793-1797
13. Liu T., Zhang M., Zhang H., Sun C., and Deng Y. Inhibitory effects of cucurbitacin B on laryngeal squamous cell carcinoma. Eur. Arch. Otorhinolaryngol. 265 10 (2008) 1225-1232
14. Chau M.N., and Banerjee P.P. Development of a STAT3 reporter prostate cancer cell line for high throughput screening of STAT3 activators and inhibitors. Biochem. Biophys. Res. Commun. 377 2 (2008) 627-631
15. Costantino L., and Barlocco D. STAT 3 as a target for cancer drug discovery. Curr. Med. Chem. 15 9 (2008) 834-843
16. Yue P., and Turkson J. Targeting STAT3 in cancer: how successful are we?. Expert. Opin. Investig. Drugs 18 1 (2009) 45-56
17. Yin D., Wakimoto N., Xing H., Lu D., Huynh T., Wang X., Black K.L., and Koeffler H.P. Cucurbitacin B markedly inhibits growth and rapidly affects the cytoskeleton in glioblastoma multiforme. Int. J. Cancer 123 6 (2008) 1364-1375
18. Aviel S., Blackhall F.H., Shepherd F.A., and Tsao M.S. K-ras mutations in non-small-cell lung carcinoma a review. Clin. Lung Cancer 8 1 (2006) 30-38
19. Akagi K., Uchibori R., Yamaguchi K., Kurosawa K., Tanaka Y., and Kozu T. Characterization of a novel oncogenic K-ras mutation in colon cancer. Biochem. Biophys. Res. Commun. 352 3 (2007) 728-732
20. Deramaudt T., and Rustgi A.K. Mutant KRAS in the initiation of pancreatic cancer. Biochim. Biophys. Acta 1756 2 (2005) 97-101
21. DeLellis R.A. Pathology and genetics of thyroid carcinoma. J. Surg. Oncol. 94 8 (2006) 662-669
22. Washburn K.B., and Neary J.T. P2 purinergic receptors signal to STAT3 in astrocytes: difference in STAT3 responses to P2Y and P2X receptor activation. Neuroscience 142 2 (2006) 411-423
23. Liu T., Zhang M., Zhang H., Sun C., and Yang X. Combined antitumor activity of cucurbitacin B and docetaxel in laryngeal cancer. Eur. J. Pharmacol. 587 1-3 (2008) 78-84
24. Haritunian T., Gueller S., Zhang L., Badr R., Yin D., Xing H., Fung M.C., and Koeffler H.P. Cucurbitacin B induces differentiation, cell cycle arrest, and actin cytoskeletal alterations in myeloid leukemia cells. Leuk. Res. 32 9 (2008) 1366-1373
25. Suggitt M., and Bibby M.C. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin. Cancer Res. 11 3 (2005) 971-981
26. Liu T., Zhang M., Deng Y., Zhang H., Sun C., Yang X., and Ji W. Effect of cucurbitacin B on cell proliferation and apoptosis in Hep-2 cells. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 22 9 (2008) 403-407
27. Jing N., and Tweardy D.J. Targeting Stat3 in cancer therapy. Anticancer Drugs 16 6 (2005) 601-607
28. Deng J., Grande F., and Neamati N. Small molecule inhibitors of Stat3 signaling pathway. Curr. Cancer Drug Targets 7 1 (2007) 91-107
29. Tannin-Spitz T., Grossman S., Dovrat S., Gottlieb H.E., and Bergtman M. Growth inhibitory activity of cucurbitacin glucosides isolated from Citrullus colocynthis on human breast cancer cells. Biochem. Pharmacol. 73 1 (2007) 56-67
30. Wierenga A.T., Vogelzang I., Eggen B.J., and Vellenga E. Erythropoietin-induced serine 727 phosphorylation of STAT3 in erthroid cells is mediated by a MEK-, ERK-, and MSK-dependent pathway. Exp. Hematol. 31 5 (2003) 398-405
31. Li L., Gao Y., Zhang L.L., and He D.L. Concomitant activation of the JAK/STAT3 and ERK1/2 signaling is involved in leptin-mediated proliferation of renal cell carcinoma Caki-2 cells. Cancer Biol. Ther. 7 11 (2008)
32. Herrera R., and Sebolt-Leopoid J.S. Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. Trends Mol. Med. 8 Suppl. 4 (2002) S27-S31
33. Schlessinger J., and Lemmon M.A. Nuclear signaling by receptor tyrosine kinases: the first robin of spring. Cell 127 1 (2006) 45-48
34. Nishioka C., Ikezoe T., Yang J., Koeffler H.P., and Yokoyama A. Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell. Leukemia 22 7 (2008) 1449-1452
35. Case M., Matheson E., Minto L., Hassan R., Harrison C.J., Bown N., Bailey S., Vormoor J., Hall A.G., and Irving J.A. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. Cancer Res. 68 16 (2008) 6803-6809
36. Wang W., Edington H.D., Jukic D.M., Rao U.N., Land S.R., and Kirkwood J.M. Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma. Cancer Immunol. Immunother. 57 9 (2008) 1315-1321
37. Diaz R., Lue J., Mathews J., Yoon A., Ahn D., Garcia-Espana A., Leonardo P., Vargas M.P., and Pellicer A. Inhibition of Ras oncogenic activity by Ras protooncogenes. Int. J. Cancer 113 2 (2005) 241-248
38. Steelman L.S., Abrams S.L., Whelan J., Bertrand F.E., Ludwig D.E., Basecke J., Libra M., Stivaia F., Milella M., Tafuri A., Lunghi P., Bonati A., Martelli A.M., and McCubrey J.A. Contributions of the Raf/MEK/ERK, PI3k/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 22 4 (2008) 686-707
39. McCubrey J.A., Steelman L.S., Abrams S.L., Bertrand F.E., Ludwig D.E., Basecke J., Libra M., Stivaia F., Milella M., Tafuri A., Lunghi P., Bonati A., and Martelli A.M. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukaemia therapy. Leukemia 22 4 (2008) 708-722